In a filing, Akero Therapeutics Inc revealed its Chief Development Officer Yale Catriona unloaded Company’s shares for reported $0.5 million on Feb 18 ’25. In the deal valued at $49.87 per share,10,000 shares were sold. As a result of this transaction, Yale Catriona now holds 95,648 shares worth roughly $4.74 million.
Then, Cheng Andrew sold 30,000 shares, generating $1,581,994 in total proceeds. Upon selling the shares at $52.73, the President and CEO now owns 686,062 shares.
Before that, Graham G. Walmsley bought 200,000 shares. Akero Therapeutics Inc shares valued at $9,600,000 were divested by the Director at a price of $48.00 per share. As a result of the transaction, Graham G. Walmsley now holds 1,000,000 shares, worth roughly $49.6 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Friday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -4.32% to $49.60. Over the last five days, the stock has lost -1.82%. Akero Therapeutics Inc shares have risen nearly 78.29% since the year began. Nevertheless, the stocks have risen 106.32% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.86 was recorded on 01/14/25. SMA at 50 days reached $37.23, while 200 days put it at $29.11.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 48.71, which if violated will result in even more drops to 47.83. On the upside, there is a resistance level at 51.33. A further resistance level may holdings at 53.07. The Relative Strength Index (RSI) on the 14-day chart is 58.78, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.82%. Stochastics %K at 22.84% indicates the stock is a holding.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
